Tasos Konidaris Amneal Pharmaceuticals, Inc. (AMRX) insider trading activity

Tasos Konidaris is Executive Vice President & CFO of Amneal Pharmaceuticals, Inc.. Currently has a direct ownership of 621,882 shares of AMRX, which is worth approximately $4.74 Million. The most recent transaction as insider was on Mar 05, 2025, when has been sold 100,000 shares (Class A Common Stock) at a price of $8.91 per share, resulting in proceeds of $891,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 622K

17.93% 3M change

17.93% 12M change

Total Value Held $4.74 Million

Tasos Konidaris Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 05 2025	SELL Open market or private sale	$891,000 $8.91 p/Share	100,000 Reduced 13.85%	621,882 Class A Common Stock
Mar 04 2025	SELL Payment of exercise price or tax liability	$198,873 $8.84 p/Share	22,497 Reduced 3.02%	721,882 Class A Common Stock
Mar 04 2025	BUY Exercise of conversion of derivative security	-	43,981 Added 5.58%	744,379 Class A Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$1,168,671 $8.76 p/Share	133,410 Reduced 16.0%	700,398 Class A Common Stock
Mar 03 2025	BUY Exercise of conversion of derivative security	-	283,789 Added 26.35%	793,061 Class A Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$116,992 $8.67 p/Share	13,494 Reduced 2.39%	550,019 Class A Common Stock
Mar 01 2025	BUY Exercise of conversion of derivative security	-	36,197 Added 6.04%	563,513 Class A Common Stock
Mar 12 2024	SELL Payment of exercise price or tax liability	$163,494 $5.31 p/Share	30,790 Reduced 5.52%	527,316 Class A Common Stock
Mar 12 2024	BUY Exercise of conversion of derivative security	-	87,720 Added 13.58%	558,106 Class A Common Stock
Mar 03 2024	SELL Payment of exercise price or tax liability	$197,045 $5.47 p/Share	36,023 Reduced 7.11%	470,386 Class A Common Stock
Mar 03 2024	BUY Exercise of conversion of derivative security	-	102,629 Added 17.3%	490,512 Class A Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$72,515 $5.47 p/Share	13,257 Reduced 3.18%	403,780 Class A Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	36,197 Added 7.99%	417,037 Class A Common Stock
Mar 12 2023	BUY Exercise of conversion of derivative security	-	87,719 Added 18.72%	380,840 Class A Common Stock
Mar 03 2023	BUY Exercise of conversion of derivative security	-	45,289 Added 13.38%	293,121 Class A Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	-	36,197 Added 12.74%	247,832 Class A Common Stock
Mar 12 2022	BUY Exercise of conversion of derivative security	-	87,719 Added 29.3%	211,635 Class A Common Stock
Mar 01 2022	BUY Exercise of conversion of derivative security	-	36,197 Added 22.61%	123,916 Class A Common Stock
Mar 12 2021	BUY Exercise of conversion of derivative security	-	87,719 Added 50.0%	87,719 Class A Common Stock

Also insider at

KDMN

Kadmon Holdings, Inc.

Director

Tasos Konidaris

Executive Vice President & CFO

Bridgewater, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMRX shares.

Notify only if

Value

Insider Trading

Get notified when an Amneal Pharmaceuticals, Inc. insider buys or sells AMRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Amneal Pharmaceuticals, Inc.

Track Activities on AMRX

Account